The findings and recommendations of the Evaluation of ISED Funding to the Centre for Drug Research and Development (CDRD) were provided to the Science Programs and Partnership Branch of the Science and Research Sector (SRS) at Innovation, Science and Economic Development Canada (ISED). Management has been consulted and agrees with the findings included in this report and will take action to address all applicable recommendations by March 31, 2023.
Recommendation | Planned Action on the Recommendation | Responsible Official | Target Completion |
---|---|---|---|
Relevance ISED's Science and Research Sector should work with adMare BioInnovations to increase understanding within the academic community of its refined focus, role and objectives in regards to advancing drug R&D projects. |
ISED Position ISED SRS agrees with the recommendation. It is important for adMare to ensure that stakeholders in the health innovation ecosystem understand its objectives, direction and priorities. In particular, its greater focus on commercialization should be clearly communicated to academia. ISED Management Response ISED SRS will support adMare's ongoing multi-pronged approach to increase understanding and alignment with the academic community, which includes:
|
Director General, Science Programs and Partnerships |
March 31, 2023
|
Efficiency ISED's Science and Research Sector should engage with adMare BioInnovations to better understand the organization's metrics and plan towards self-sustainability. |
ISED Position ISED SRS agrees with the recommendation. Understanding adMare's level of self-sustainability, and plans to advance it, will help enhance the efficiency of the program. ISED Management Response ISED SRS will engage with adMare in a series of meetings to discuss and gain alignment on the following:
|
Director General, Science Programs and Partnerships |
March 31, 2023
|